All In Biotech

Drug Trial Radar · NCT06731374

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

A Phase IV, Experimental Human Pneumococcal Challenge (EHPC) Model to Investigate Streptococcus Pneumoniae Serotype 3 (SPN3) Colonisation Following PCV15, a Double Blind Randomised Controlled Trial (DBRCT) in Healthy Participants Aged 18 - 50 Years in the UK.

Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Feb 24, 2025

Primary completion

Dec 2025

Study completion Dec 2026

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Liverpool School of Tropical Medicine, United Kingdom; Oxford University Hospitals NHS Trust
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Streptococcus pneumoniae (pneumococcus) is a bacterium that causes just under four million serious infections every year. It is normal for pneumococcus bacteria to live in the noses of healthy adults and children as part of the nasal microflora without causing harm. This is called "carriage". But the bacteria can still be passed on to other people. If they are at-risk, for example elderly, or very young, or have pre-existing health conditions, the pneumococcus bacteria can cause pneumonia, which can cause serious life-threatening illness. Pneumococcus bacteria are surrounded by a sugar capsule. But the capsule does not always have the same components. As a result, the bacteria are classified into more than 100 different types. To make them effective, the vaccines that are currently available contain the sugar capsules of the most common pneumococcal types that cause disease. One such vaccine - PCV13 - has been effective globally in protecting against pneumococcus disease. It works because it controls the "carriage" (how a person carries the bacteria in their nose) of 13 types of the bacteria. Vaccines giving protection against other types of the bacteria are also becoming available worldwide. PCV15 is similar to PCV13 and protects against two additional types of the bacteria so may offer more protection. This study, which lasts 2 months and is funded by Merck Sharp \& Dohme (MSD), aims to assess if using PCV15 can protect against "carriage". To do this, investigators will use a well-established method already used with more than 2,000 people safely in other research. This involves "challenging" volunteers by putting a small amount of the pneumococcus bacteria into their noses. In this study, before they are challenged, volunteers will either be vaccinated with the real PCV15 vaccine or a dummy ("placebo"). The Investigators will then be able to compare the two groups to find out who the vaccine protected and who it did not. After the study everyone who takes part and fit into certain criteria will be given antibiotics to clear the pneumococcus colonisation. They will also be regularly monitored during the study to ensure their safety. A very small number of volunteers will be asked to have a biopsy to collect tissue samples from inside their nose before and after being vaccinated with PCV15. This will help researchers to understand more about how the immune system responds to the vaccine. The information gain in this project will help the investigators to understand how exactly PCV15 vaccine protects people against pneumococcus. This means that this vaccine and future pneumococcal vaccines will be improved to protect many lives in future around the world.

Conditions

  • Pneumococcal Disease
  • Pneumococcal Carriage

Interventions

  • PCV15Biological

    VAXNEUVANCE (Merck, Sharp \& Dohme LLC, a subsidiary of Merck \& Co, Inc., Rahway, NJ, USA \[MSD\]) is a 15-valent PCV containing capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, and 33F adjuvanted with aluminium phosphate.

  • Streptococcus pneumoniae serotype 3Biological

    Streptococcus pneumoniae SPN3 (Clade Ia, strain LIV014-S3) - Single inoculation at 80,000 colony-forming unit (CFU)/naris, 28 days after vaccination.

  • PlaceboBiological

    The placebo consists of 0.9% sodium chloride for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence or absence of experimental SPN3 colonisation acquisitionTime frame: Days 2, 7, 14 and 28 following experimental challenge

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Liverpool Vaccine Group

    Liverpool, North West, United Kingdom · Recruiting

  • Oxford Vaccine Group

    Oxford, Oxfordshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.